Urological screening means checking for certain conditions before symptoms appear. It differs from investigating symptoms such as blood in urine, burning, a weak stream or difficulty emptying the bladder.

Not everyone needs a yearly package of urine tests, scans, PSA testing and cystoscopy. The appropriate assessment depends on the condition being considered, personal risk, overall health and whether testing is likely to offer a meaningful benefit.

Understanding the purpose and limitations of each test can help you make an informed decision.

Screening, Diagnosis and Follow-Up: What Is the Difference?

The same investigation may serve different purposes depending on why it is requested.

A test used to investigate symptoms is not automatically suitable for screening people who feel well.

A — Assess Your Personal Risk

Before arranging screening, a clinician considers whether your circumstances make a particular test appropriate.

For prostate cancer screening, relevant factors may include:

• Age.
• Family history of prostate cancer.
• Known inherited cancer-related genetic changes.
• Previous PSA results.
• Overall health and life expectancy.
• Your preferences about further investigations and treatment.

Screening recommendations vary between professional organisations. Some people at increased risk may benefit from an earlier discussion, while others may gain little benefit from testing. The decision should be individual rather than based on a universal schedule. EAU Guidelines on Prostate Cancer

Symptoms require a separate assessment. A person with urinary bleeding or difficulty passing urine should not wait until reaching a screening age.

B — Balance the Benefits and Possible Harms

Screening can sometimes identify disease before symptoms develop, when management options may differ. However, finding a condition earlier does not always improve an individual’s health.

Possible disadvantages include:

• False-positive results: An abnormal test suggests disease that is not present.
• False-negative results: A reassuring result misses an existing condition.
• Overdiagnosis: Testing identifies disease that would never have caused harm.
• Additional procedures: Results lead to further imaging, biopsy or other investigations.
• Anxiety and treatment effects: Further assessment or treatment may have physical and emotional consequences.

These considerations are particularly relevant to PSA-based prostate cancer screening. A decision should include what might happen after an abnormal result. 

C — Choose Tests for a Clear Clinical Reason

Different urological tests answer different questions. They are not interchangeable, and no single test checks every aspect of urinary health.

PSA Blood Test

Prostate-specific antigen, or PSA, is a protein produced by the prostate. A blood test measures its concentration.

PSA may rise because of prostate cancer, but benign prostate enlargement and inflammation can also raise it. An elevated PSA result does not confirm cancer.

Depending on the circumstances, further assessment may involve repeating the test, reviewing possible temporary influences, estimating risk or considering MRI and biopsy. A lower result also cannot completely exclude cancer.

The National Cancer Institute’s PSA information explains its uses and limitations.

Digital Rectal Examination

A digital rectal examination allows a clinician to assess the prostate through the rectum using a gloved, lubricated finger.

It may contribute to an assessment when clinically indicated, but it cannot independently confirm or exclude prostate cancer. Its role should be explained alongside the purpose of other investigations. EAU Guidelines on Prostate Cancer

For background information, read about prostate conditions.

Urine Tests

Urine testing may help investigate infection, blood or other abnormalities.

The result needs to be interpreted alongside symptoms, medical history and the reason for testing. A urine test alone does not provide a complete assessment of the urinary system.

Ultrasound

An ultrasound may help assess the kidneys and bladder or measure urine remaining after urination. It can provide useful information about selected structural concerns.

However, ultrasound cannot detect every urinary condition or exclude every cancer. Its usefulness depends on the question being investigated. 

Uroflowmetry and Post-Void Residual Measurement

Uroflowmetry measures the pattern and speed of urine flow. A post-void residual measurement assesses how much urine remains in the bladder after urination.

These tests may help evaluate reduced flow or incomplete emptying. They generally form part of a symptom-based assessment rather than routine cancer screening. 

Cystoscopy

Cystoscopy uses a thin instrument with a camera to examine the urethra and bladder.

It may be recommended to investigate blood in urine, selected persistent urinary symptoms or abnormal findings. It is also used in follow-up for some established conditions.

Cystoscopy is not a standard annual test for every adult. Its purpose, preparation and possible complications should be discussed before the procedure.

Read the NIDDK explanation of cystoscopy.

Does Everyone Need Bladder Cancer Screening?

Routine bladder cancer screening is not established as beneficial for all adults without symptoms. The US Preventive Services Task Force considers the evidence insufficient to determine the balance of benefits and harms in asymptomatic adults. This is different from recommending that urinary symptoms be ignored.
In particular, visible blood in urine needs prompt investigation, even if it happens once or is painless.

People previously treated for bladder cancer may need a specific surveillance programme. That programme is follow-up care rather than general population screening.

When Symptoms Need Assessment Instead of Screening

Arrange medical assessment for persistent or unexplained:

• Blood in urine.
• Burning or pain during urination.
• A weak or interrupted stream.
• Difficulty starting urination.
• A feeling of incomplete bladder emptying.
• Recurrent urinary infections.
• Urinary leakage or troublesome urgency.

You can read more about common symptoms in this beginner’s guide to urinary health.

Visible blood should be checked even when there is no pain. It should not automatically be attributed to infection or ageing. The NHS guidance on blood in urine explains why assessment matters.

Sudden inability to pass urine requires immediate medical attention. Fever or shaking chills with side or back pain, especially with vomiting or feeling very unwell, also requires urgent assessment. 

Questions to Ask Before Agreeing to a Test

An informed discussion can include:

1. What condition is this test looking for?
2. Is it screening, investigation of symptoms or follow-up?
3. How does my personal risk affect the decision?
4. What are the test’s limitations?
5. What might happen if the result is abnormal?
6. Could the result change my care?
7. What are the alternatives, including choosing not to test now?

Bring previous reports, relevant scan images and a current medicine list. These records can help avoid unnecessary repetition and provide context for interpreting results.